Continuous Glucose Monitoring– tag –
-
Epocrates Explains: Ketone Tracking Integrated into CGM with First-of-its-Kind Wearable, Enhancing Diabetic Ketoacidosis Prevention
Epocrates USA Overview Epocrates reports that Abbott's Libre Duo 10 Day system is the first wearable device to integrate ketone tracking with continuous glucose monitoring (CGM). This system provides real-time ketone trend data alongside... -
Abbott Wins FDA Nod for World’s First Dual Glucose-Ketone Sensor, Bolstering Diabetic Ketoacidosis Prevention
MDO Online USA Overview Abbott's Libre Duo 10 Day has received FDA authorization as the world's first Continuous Glucose Monitoring (CGM) system capable of continuously tracking both glucose and ketone levels. Developed to prevent diabet... -
FDA Approves World’s First Dual Glucose-Ketone Continuous Monitoring Wearable for Diabetes Patients: Early DKA Risk Detection Enabled
GIGAZINE Japan Overview GIGAZINE reports that the U.S. FDA has approved the world's first wearable device for continuous dual glucose and ketone monitoring in diabetes patients. This is Abbott's Libre Duo 10 Day, providing real-time data... -
HME News Reports: Abbott Gains FDA Clearance for Dual Sensing Technology, Marking New Step in DKA Prevention
HME News USA Overview HME News reports Abbott has received FDA authorization for its Libre Duo 10 Day system, which continuously monitors both glucose and ketones. This biowearable is designed to alert patients to rising ketone levels, c... -
South Korea’s i-SENS Pioneers Connected Diabetes Care Future with Enhanced Biosensor Accuracy and CGM Innovation, Accelerating Global Expansion
i-SENS (Interview) South Korea Overview Hakhyun Nam, CEO of South Korean diagnostic medical device company i-SENS, articulated the company's vision to enhance global access to advanced diagnostic solutions through superior biosensor accu... -
From Wearables to Digital Twins: AI-Driven Biomarkers Reshape Personalized and Predictive Medicine
ceapress.org USA Overview Wearable technologies are rapidly transforming from consumer fitness devices into indispensable tools for medical research and healthcare. Continuously collecting vast physiological and behavioral data, these sy... -
Dexcom’s Investment Outlook Brightens as G7 CGM Gains Expanded Reimbursement for Type 2 Non-Insulin Diabetes Patients
Seeking Alpha USA Overview Dexcom's investment thesis has significantly improved following expanded insurance reimbursement for its G7 continuous glucose monitoring (CGM) systems, now covering a large population of type 2 non-insulin dia... -
Dexcom EVP Kevin R. Sayer to Sell $2.4M in Company Stock by August 20, 2026
SEC Filing - Form 144 / Seeking Alpha USA Overview Dexcom, Inc. Executive Vice President Kevin R. Sayer filed a Rule 144 notice to sell 26,756 shares of common stock, approximately $2.4 million in value, with an anticipated sale date of ... -
Microneedle Sensors Revolutionize Non-Invasive Glucose Monitoring with 2026 OTC Launch, Enabling Personalized Metabolic Optimization
Unknown Unknown Overview Slated for a 2026 market entry, microneedle sensors are poised to redefine non-invasive glucose monitoring, offering unparalleled accuracy and practicality. A 14-day over-the-counter (OTC) starter pack will empow... -
CNET Reviews 2026’s Latest Continuous Glucose Monitors (CGM), Highlighting FDA-Approved Dexcom Stelo’s Integration with Oura Ring
CNET USA Overview CNET's 2026 review of Continuous Glucose Monitors (CGM) features Abbott Freestyle Libre 2 and 3 Plus, Dexcom G7, and the notable Stelo by Dexcom, the first FDA-approved over-the-counter CGM in the US (2024). Stelo's sea...
